Home » MILLENNIUM BEGINS VELCADE TRIAL
MILLENNIUM BEGINS VELCADE TRIAL
Millennium Pharmaceuticals has started a Phase III trial of Velcade with rituximab to study progression-free survival in patients with relapsed or refractory follicular lymphoma, a subtype of non-Hodgkin's lymphoma.
The study will be conducted in about 670 patients and be given a weekly dose of Velcade of 1.6 mg/m2 and rituximab of 375 mg/m2.
Velcade is for the treatment of multiple myeloma patients who have received at least one prior therapy. Secondary endpoints of the study include overall response rate and duration of response.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May